Mucosis

Mucosis B.V., founded in 2006, is a Dutch biotechnology company specializing in needle-free mucosal vaccines administered via the nose or mouth. Their flagship product, SynGEM®, an intranasal vaccine targeting respiratory syncytial virus infection, is based on the patented and validated Mimopath® technology. This technology aims to elicit a more natural immune response and provide broad protection, as evidenced in animal and human trials for their FluGEM® vaccine candidate. The company recently received a €5.70M Venture Round investment on January 20, 2016, with funding from BioGeneration Ventures and the Wellcome Trust, marking a significant milestone for their continued development. Mucosis operates within the Biotechnology and Health Care industries and is pioneering the field of needle-free mucosal vaccines, aiming to establish natural and robust immunity. Mucosis' dedication to innovation and their success in securing investments from key venture capitalists demonstrate the potential of their novel approach to vaccine development and their commitment to addressing critical healthcare challenges.